N/A Completed N=248

A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia

COVID

Source: ClinicalTrials.gov NCT06016556 ↗

Enrolled (actual)

248

Serious AEs

0.8%

Results posted

Apr 2025

Primary outcomePrimary: Number of Participants Classified According to Education Level at Index Date — 32; 1; 22; 85 Participants

Summary

The aim of this study is to describe the baseline demographic, clinical characteristics, and Healthcare Resource Use (HCRU) of adult (≥18 years) COVID-19 patients who have been prescribed nirmatrelvir, ritonavir treatment.

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Classified According to Education Level at Index Date	32; 1; 22; 85; 0; 0	—
PRIMARY Number of Participants Classified According to Employment Status at Index Date	41; 1; 10; 42; 11; 3	—
PRIMARY Height at Index Date	1.62	—
PRIMARY Weight at Index Date	74.13	—
PRIMARY Body Mass Index (BMI) at Index Date	28.25	—
PRIMARY Number of Participants Classified According to Smoking Status at Index Date	8; 7; 207	—
PRIMARY Number of Participants Who Had at Least 1 Pre-existing Comorbidity at Index Date	224	—
PRIMARY Number of Participants Who Had at Least 1 Concomitant Medication for Comorbidities at Index Date	186	—
PRIMARY Number of Participants With COVID-19 Infection During the Last 6 Months Prior to Index Date	9	—
PRIMARY Duration Between Last COVID-19 Infection and Index Date	3.34	—
PRIMARY Number of Participants Who Had Previously Received at Least 1 Dose of Any COVID-19 Vaccine	200	—
PRIMARY Number of Participants Classified According to the Type of COVID-19 Vaccine Received Previously	1; 1; 143; 19	—
PRIMARY Duration Between Previous COVID-19 Vaccination Date and Index Date	23.16	—
PRIMARY Number of Participants Classified According to Total Number of Previous COVID-19 Vaccine Doses Taken	10; 45; 84; 7	—
PRIMARY Number of Participants Classified According to Dose of Nirmatrelvir/Ritonavir Received at Index Date	229; 19	—
PRIMARY Number of Participants Classified According to Frequency of Dosing of Nirmatrelvir/Ritonavir (PAXLOVIDTM) at Index Date	245; 2; 1	—
PRIMARY Number of Participants Classified According to Dispensed Type of Nirmatrelvir/Ritonavir (PAXLOVIDTM) at Index Date	236; 11; 1	—
PRIMARY Number of Participants Classified According to Medications Used to Treat COVID-19 Infection at Index Date	13; 11; 8; 7; 5; 3	—
PRIMARY Number of Participants Who Were Hospitalized at Index Date	120	—
PRIMARY Number of Participants Who Were Hospitalized Due to COVID-19 at Index Date	72	—
PRIMARY Length of Hospitalization Stay Due to COVID-19 at Index Date	6.64	—
PRIMARY Number of Participants With Intensive Care Unit (ICU) Admission at Index Date	17	—
PRIMARY Length of ICU Stay Due to COVID-19 at Index Date	17.83	—
PRIMARY Number of Participants Who Were on Supplemental Oxygen Use at Index Date	14	—
PRIMARY Number of Participants Who Were on Vasopressor Use at Index Date	—	—
PRIMARY Number of Participants With Intubation at Index Date	2	—
PRIMARY Number of Participants With Outpatient Visits at Index Date	32	—
PRIMARY Number of Participants Who Had Emergency Room (ER) Visits Due to COVID-19 at Index Date	126	—
SECONDARY Number of Participants Who Were Hospitalized During the 30-day Post-Index Period	23	—
SECONDARY Number of Participants Who Were Hospitalized Due to COVID-19 During the 30-day Post-Index Period	2	—
SECONDARY Length of Hospitalization Stay Due to COVID-19 During the 30-day Post-Index Period	23.00	—
SECONDARY Number of Participants With ICU Admission During the 30-day Post-Index Period	9	—
SECONDARY Length of ICU Stay Due to COVID-19 During the 30-day Post-Index Period	8.00	—
SECONDARY Number of Participants Who Were on Supplemental Oxygen Use During the 30-day Post-Index Period	6	—
SECONDARY Number of Participants Who Were on Vasopressor Use During the 30-day Post-Index Period	1	—
SECONDARY Number of Participants With Intubation During the 30-day Post-Index Period	2	—
SECONDARY Number of Participants Who Had Outpatient Visits During the 30-day Post-Index Period	61	—
SECONDARY Number of Participants Who Had ER Visits Due to COVID-19 During the 30-day Post-Index Period	21	—
SECONDARY Number of Participants Classified According to COVID-19 Polymerase Chain Reaction (PCR) and Antigen Test Results During the 30-day Post-Index Period	4; 1; 7; 5	—
SECONDARY Time to Negative COVID-19 Test During the 30-day Post-Index Period	15.09	—

Eligibility Criteria

Inclusion Criteria

Confirmed COVID-19 infection during the study observation period
Nirmatrelvir, ritonavir written prescription

Exclusion Criteria

None

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06016556). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.